[go: up one dir, main page]

WO2001062240A3 - Utilisation d'un detergent de type zwittergent pour la preparation d'une composition pharmaceutique destinee a etre administree par voie nasale - Google Patents

Utilisation d'un detergent de type zwittergent pour la preparation d'une composition pharmaceutique destinee a etre administree par voie nasale Download PDF

Info

Publication number
WO2001062240A3
WO2001062240A3 PCT/FR2001/000500 FR0100500W WO0162240A3 WO 2001062240 A3 WO2001062240 A3 WO 2001062240A3 FR 0100500 W FR0100500 W FR 0100500W WO 0162240 A3 WO0162240 A3 WO 0162240A3
Authority
WO
WIPO (PCT)
Prior art keywords
zwitterion
preparing
pharmaceutical composition
nasal delivery
type detergent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2001/000500
Other languages
English (en)
Other versions
WO2001062240A2 (fr
Inventor
Liliane Goestch
Nathalie Corvaia
Alain Beck
Jean-Francois Haeuw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to AU35729/01A priority Critical patent/AU3572901A/en
Publication of WO2001062240A2 publication Critical patent/WO2001062240A2/fr
Publication of WO2001062240A3 publication Critical patent/WO2001062240A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne l'utilisation d'un détergent de type zwittergent, notamment le ZW 3-14 (3-(N-tétradécyl-N, N-diméthyl-amino)-propane-1-sulfonate), pour la préparation d'une composition pharmaceutique destinée à être administrée par voie nasale pour indure ou améliorer l'immunité d'un mammifère vis-à-vis d'un antigène ou d'un haptène qui lui est associé. L'invention comprend également l'utilisation de tels zwittergents dans des compositions pharmaceutiques, notamment vaccinales, pouvant contenir en outre un composé porteur et un adjuvant, pour le traitement prophylactique etthérapeutique des infections ou des tumeurs. Lesdites compositions pharmaceutiques sont également comprises dans la présente invention.
PCT/FR2001/000500 2000-02-21 2001-02-21 Utilisation d'un detergent de type zwittergent pour la preparation d'une composition pharmaceutique destinee a etre administree par voie nasale Ceased WO2001062240A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU35729/01A AU3572901A (en) 2000-02-21 2001-02-21 Use of zwitterion-type detergent for preparing a pharmaceutical composition for nasal delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0002104A FR2805163A1 (fr) 2000-02-21 2000-02-21 Utilisation d'un detergent de type zwittergent pour la preparation d'une composition pharmaceutique destinee a etre administree par voie nasale
FR00/02104 2000-02-21

Publications (2)

Publication Number Publication Date
WO2001062240A2 WO2001062240A2 (fr) 2001-08-30
WO2001062240A3 true WO2001062240A3 (fr) 2002-03-14

Family

ID=8847190

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/000500 Ceased WO2001062240A2 (fr) 2000-02-21 2001-02-21 Utilisation d'un detergent de type zwittergent pour la preparation d'une composition pharmaceutique destinee a etre administree par voie nasale

Country Status (3)

Country Link
AU (1) AU3572901A (fr)
FR (1) FR2805163A1 (fr)
WO (1) WO2001062240A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2058002A1 (fr) * 2007-10-31 2009-05-13 Bestewil Holding B.V. Membranes reconstituées du virus respiratoire syncytial et utilisation en tant que vaccin contre le virus respiratoire syncytial
EP2879691B1 (fr) 2012-08-06 2019-03-27 Biogen MA Inc. Procédés d'inactivation de virus enveloppés

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005194A1 (fr) * 1990-09-25 1992-04-02 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Vaccin adapte a la lutte contre bordetella pertussis
WO1996017863A1 (fr) * 1994-12-07 1996-06-13 Idec Pharmaceuticals Corporation Obtention de reactions lymphocytaires t cytotoxiques
FR2766192A1 (fr) * 1997-07-17 1999-01-22 Pf Medicament Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
FR2776521A1 (fr) * 1998-03-27 1999-10-01 Pf Medicament Utilisation de conjugues p40 actifs par voie nasale

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005194A1 (fr) * 1990-09-25 1992-04-02 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Vaccin adapte a la lutte contre bordetella pertussis
WO1996017863A1 (fr) * 1994-12-07 1996-06-13 Idec Pharmaceuticals Corporation Obtention de reactions lymphocytaires t cytotoxiques
FR2766192A1 (fr) * 1997-07-17 1999-01-22 Pf Medicament Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
FR2776521A1 (fr) * 1998-03-27 1999-10-01 Pf Medicament Utilisation de conjugues p40 actifs par voie nasale

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BASTIEN, NATHALIE ET AL: "Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines", VACCINE (1999), 17(7-8), 832-836, XP000972782 *
IDANPAAN-HEIKKILA ILONA ET AL: "Immunization with meningococcal class 1 outer membrane protein produced in Bacillus subtilis and reconstituted in the presence of Zwittergent or Triton X-100.", VACCINE, vol. 14, no. 9, 1996, pages 886 - 891, XP004057614, ISSN: 0264-410X *
JEURISSEN S H M ET AL: "INDUCTION OF MUCOSAL IMMUNOGLOBULIN A IMMUNE RESPONSE BY PREPARATIONS OF NEISSERIA-GONORRHOEAE PORIN PROTEINS", INFECTION AND IMMUNITY, vol. 55, no. 1, 1987, pages 253 - 257, XP000972580, ISSN: 0019-9567 *
KYD JENNELLE M ET AL: "Conservation of Immune Responses to Proteins Isolated by Preparative Polyacrylamide Gel Electrophoresis from the Outer Membrane of Nontypeable Haemophilus influenzae.", INFECTION AND IMMUNITY, vol. 62, no. 12, 1994, pages 5652 - 5658, XP002013974, ISSN: 0019-9567 *
MAZHUL' L A ET AL: "USE OF ZWITTERIONIC DETERGENT SULFOBETAINE 12 FOR THE PREPARATION OF VIROSOMES AND INVESTIGATION OF THEIR IMMUNOGENIC AND PROTECTIVE PROPERTIES", MOLEKULYARNAYA GENETIKA MIKROBIOLOGIYA I VIRUSOLOGIYA, no. 12, 1988, pages 42 - 47, XP000974342, ISSN: 0208-0613 *
WEDEGE, E. ET AL: "Restoration of antibody binding to blotted meningococcal outer membrane proteins using various detergents", J. IMMUNOL. METHODS (1988), 113(1), 51-9, XP000971124 *

Also Published As

Publication number Publication date
WO2001062240A2 (fr) 2001-08-30
AU3572901A (en) 2001-09-03
FR2805163A1 (fr) 2001-08-24

Similar Documents

Publication Publication Date Title
WO2000062800A3 (fr) Vaccins
WO2004087153A3 (fr) Utilisation de petites molecules de composes pour une immunopotentialisation
AU2168902A (en) Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol
WO2002009746A8 (fr) Composition vaccinale
IL151355A0 (en) Vaccine for the treatment of artherosclerosis
HUP0400445A3 (en) Novel vaccine composition
WO2009060281A3 (fr) Analogues d'oligoribonucléotides immunostimulants contenant des fractions oligophosphates modifiées
HK1043943A1 (zh) 肺炎链球菌蛋白质和疫苗
PL351894A1 (en) Novel compositions
WO2003051394A3 (fr) Particules de phosphate de calcium utilisees comme adjuvants pour la muqueuse
AU2457100A (en) Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
WO2002087494A3 (fr) Nouveau vaccin
NO331017B1 (no) Glukan, adjuvanssammensetning omfattende glukanet samt anvendelse av glukanet for fremstilling av en mukosal administrerbar adjuvanssammensetning.
AU2151902A (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
AU5162201A (en) Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
AU2002221519A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
HUP0303942A3 (en) Novel vaccine composition
WO2001074394A8 (fr) Nouvelle combinaison d'un betabloquant et d'un hypocholesterolemiant
WO2001062240A3 (fr) Utilisation d'un detergent de type zwittergent pour la preparation d'une composition pharmaceutique destinee a etre administree par voie nasale
WO2003037371A3 (fr) Agonistes de kinase amp ou promedicaments d'adenosine en tant qu'agents immunostimulants
WO2000062802A3 (fr) Vaccin
MY127452A (en) Vaccines.
WO2002040518A8 (fr) Domaine periplasmique d'une proteine omp d'enterobacterie et son utilisation comme porteur ou adjuvant
WO2002053184A3 (fr) Utilisations de composes polycationiques
WO2002030458A8 (fr) Composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN JP MX US ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN JP MX US ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP